Zydus Lifesciences Extends Sterling API Deal to September 2026

Zydus Lifesciences Limited has extended the closing date for acquiring Sterling Biotech Limited's active pharmaceutical ingredient business to September 30, 2026. The Rs 84 crore transaction remains subject to pending conditions precedent, delaying the transfer of a fermentation-based API portfolio and manufacturing facility near Vadodara, Gujarat.

Why did Zydus extend the Sterling Biotech API deal?

Zydus extended the transaction deadline because Sterling Biotech Limited is still completing conditions required under the business transfer agreement. Both parties mutually agreed to revise the closing date to September 30, 2026, after the acquisition was originally expected to close by December 31, 2024 and was subsequently extended to June 30, 2026.

The extension does not change the stated purchase consideration or the strategic rationale for the deal. It means the business transfer cannot be completed until the agreed pre-closing requirements are fulfilled. Zydus has described the transaction as continuing to be subject to those conditions rather than indicating that it has been cancelled.

What is Zydus buying from Sterling Biotech?

Zydus is buying Sterling Biotech's target API business on a going-concern basis for a pre-defined lump-sum consideration of Rs 84 crore. The business transfer agreement was approved by Zydus' board on September 17, 2024, following the company's acquisition of a 50% stake in Sterling Biotech through a wholly owned subsidiary.

The target business includes fermentation-based API products such as Lovastatin, Daunorubicin, Doxorubicin and Epirubicin. It also includes a manufacturing facility at Masar near Vadodara in Gujarat. The transfer has been structured as a slump sale, with no separate values assigned to individual assets and liabilities, on a cash-free and debt-free basis.

Why is the API business important to Zydus?

The Sterling Biotech business is relevant to Zydus because it adds fermentation-based API manufacturing capabilities. Zydus has said the portfolio is an appropriate strategic fit, citing the high entry barriers and attractive margin profile associated with this category of API manufacturing.

The Masar facility is close to Zydus' existing facility at Dabhasa, which gives the proposed acquisition an operational rationale alongside the product portfolio. Zydus has said the transaction is intended to help meet its strategic and commercial objectives and strengthen its API manufacturing footprint through backward integration.

Fermentation-based APIs require specialised production capabilities, making manufacturing assets and established product portfolios material considerations for pharmaceutical companies. The acquisition would bring the target business under Zydus once the pending requirements are completed and the closing occurs.

What does the deadline extension mean for investors and operations?

The deadline extension is a procedural update because the purchase agreement remains in place, but the business transfer has not yet closed. Investors will be watching whether the remaining conditions are completed before September 30, 2026, as that date is now the agreed deadline for the transaction.

No share-price movement, revised deal value or change in the target business's reported turnover was disclosed in the information available. The extension also does not provide a timeline for completing each condition precedent. Until closing, the acquired API business and its Masar facility remain outside Zydus' completed operating assets.

For the wider pharmaceutical industry, the transaction underlines the value placed on API supply capabilities and manufacturing proximity. Zydus' existing API facilities at Ankleshwar and Dabhasa received Establishment Inspection Reports from the US Food and Drug Administration for inspections conducted in March 2025 and April 2025, respectively, according to the company commentary provided.

How does this deal fit Zydus' broader business position?

Zydus' India geography, comprising formulations and consumer wellness, accounted for 37% of total revenue during the referenced quarter and grew 6% year-on-year. Its branded formulations business in India grew 9% year-on-year during that quarter, supported by pillar brands and innovation products.

Those figures relate to the company's existing operations and do not include a completed transfer of Sterling Biotech's API business. The delayed acquisition is therefore a separate operational matter, focused on enlarging Zydus' manufacturing and API capabilities rather than its reported India formulations growth.

Conclusion

Zydus has retained its plan to acquire Sterling Biotech's fermentation-based API business for Rs 84 crore, but the completion timetable has moved to September 30, 2026. The target business adds products including Lovastatin, Daunorubicin, Doxorubicin and Epirubicin, along with a Gujarat manufacturing facility near Zydus' Dabhasa site.

The next disclosed milestone is the revised September 30, 2026 closing date. Progress will depend on Sterling Biotech completing the conditions precedent set out in the business transfer agreement and on the parties completing the transaction under its agreed terms.